Advanced Medical Solutions Group PLC (AMS), the UK-based wound care and surgical specialities company, has disclosed that Société Générale reduced its voting stake below the 5% threshold on 12 November 2026. The French banking group's holding fell from 5.122465% to 4.607029%, representing 10,188,045 voting rights. The TR-1 regulatory notification, filed under the Financial Conduct Authority's Disclosure and Transparency Rules, was submitted to AMS on 13 November 2026, making the change a matter of public record and a development investors in the company may wish to monitor.
Key Points
- Advanced Medical Solutions Group PLC (AMS), ISIN GB0004536594, UK-listed wound care and surgical products manufacturer
- Société Générale's total voting rights position in AMS fell from 5.122465% to 4.607029%, crossing below the 5% regulatory notification threshold
- The threshold was crossed on 12 November 2026; AMS was notified on 13 November 2026; Société Générale holds 10,188,045 direct voting rights
- Investors should watch whether further disposals reduce Société Générale's position toward the next notifiable threshold
Société Générale's AMS Stake Drops to 4.607029% After 12 November Disposal
The TR-1 standard notification form confirms that Société Générale, registered in London, acquired or disposed of voting rights in Advanced Medical Solutions Group PLC, triggering a threshold crossing on 12 November 2026. The resulting position stands at 4.607029% of total voting rights, all held as direct voting rights with no financial instruments such as options or contracts for difference forming any part of the disclosed stake. The previous notified position was 5.122465%, meaning the reduction amounts to approximately 0.515 percentage points on a reported basis. The company did not disclose the specific number of shares sold in the announcement.
AMS's Wound Care and Surgical Focus Provides Context for Institutional Investor Movements
Advanced Medical Solutions Group PLC is a UK-headquartered developer and manufacturer of products used in wound care and surgical applications, operating across international markets. The company's portfolio spans tissue-adhering products, haemostats, and advanced wound care dressings sold to healthcare providers. Institutional shareholding movements in companies of this nature are closely monitored by the market, as changes in major holdings by financial institutions such as Société Générale can reflect portfolio rebalancing or broader strategic decisions. The announcement itself does not provide any operational or financial update relating to AMS's underlying business performance.
No Financial Instruments or Proxy Arrangements Disclosed in Société Générale's TR-1 Filing
The TR-1 notification confirms that Société Générale's entire position of 10,188,045 voting rights is held directly, with no indirect holdings, financial instruments, or proxy voting arrangements disclosed. The filing also states that Société Générale is not controlled by any natural person or legal entity in connection with this notification, and does not control any other undertaking holding an interest in AMS. The form was completed on 13 November 2026 in London. No additional information was provided in sections 10 or 11 of the standard notification form.



Please wait processing your request...